Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 232.79M | 224.26M | 183.01M | 138.83M | 117.06M | 131.31M |
Gross Profit | 136.30M | 133.20M | 112.78M | 84.68M | 73.41M | 80.11M |
EBITDA | 39.55M | 42.31M | 36.71M | 24.03M | 21.84M | 30.54M |
Net Income | 12.29M | 11.27M | 10.24M | 6.22M | 9.13M | 31.53M |
Balance Sheet | ||||||
Total Assets | 128.96M | 177.07M | 154.90M | 117.04M | 117.96M | 112.56M |
Cash, Cash Equivalents and Short-Term Investments | 10.16M | 17.54M | 12.84M | 16.91M | 28.41M | 30.98M |
Total Debt | 6.76M | 6.87M | 10.32M | 694.00K | 6.52M | 11.13M |
Total Liabilities | 5.84M | 43.77M | 41.00M | 19.95M | 23.14M | 30.87M |
Stockholders Equity | 134.76M | 131.39M | 113.89M | 97.09M | 94.82M | 81.69M |
Cash Flow | ||||||
Free Cash Flow | -6.48M | 1.32M | 19.12M | 4.85M | 2.75M | 22.07M |
Operating Cash Flow | 40.77M | 39.09M | 45.21M | 27.75M | 22.49M | 35.11M |
Investing Cash Flow | -33.86M | -30.70M | -52.11M | -23.98M | -19.75M | -8.41M |
Financing Cash Flow | -4.05M | -3.69M | 2.83M | -15.27M | -5.32M | -9.07M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $276.67M | 23.73 | 9.79% | ― | 19.97% | 17.21% | |
60 Neutral | $237.83M | 15.29 | 8.12% | ― | 5.96% | -43.83% | |
56 Neutral | $275.75M | ― | 0.65% | ― | 61.50% | 34.99% | |
55 Neutral | $139.31M | ― | -407.50% | ― | 32.24% | -66.93% | |
54 Neutral | $274.75M | ― | -6.35% | ― | -32.70% | 94.89% | |
48 Neutral | $326.14M | ― | -30.11% | ― | 15.32% | 15.73% | |
46 Neutral | C$192.85M | -4.28 | -8.56% | 2.83% | 13.52% | -1.74% |
On July 2, 2025, Viemed Healthcare announced the completion of its acquisition of Lehan’s Medical Equipment, a provider of home medical equipment based in Illinois, for a base purchase price of $26 million plus contingent payments. This acquisition is expected to enhance Viemed’s market presence by combining Lehan’s established brand and expertise with Viemed’s national scale and care delivery model. Viemed plans to update its full-year 2025 financial guidance to reflect the acquisition’s contribution when reporting earnings for the quarter ended June 30, 2025.
The most recent analyst rating on (VMD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.
On June 6, 2025, Viemed Healthcare announced that its Board of Directors approved a share repurchase program, allowing the company to buy back up to 1,976,441 common shares, representing approximately 5% of the total issued and outstanding shares as of March 31, 2025. This move, effective through June 2026, is part of Viemed’s strategy to enhance shareholder value, supported by strong first-quarter results and ample liquidity, including a $55 million credit facility, while continuing to fund its growth initiatives.
The most recent analyst rating on (VMD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.
On June 5, 2025, Viemed Healthcare, Inc. held its Annual General and Special Meeting of Shareholders, where several key decisions were made. Shareholders approved an amendment to the 2024 Long Term Incentive Plan, which increases the number of shares available, clarifies vesting in the event of a change in control, and sets a minimum one-year vesting period. Additionally, all seven director nominees were elected, Ernst & Young LLP was appointed as the independent auditor, and the executive compensation package was approved. The frequency of future advisory votes on executive compensation was also set to occur annually.
The most recent analyst rating on (VMD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.
On May 6, 2025, Viemed Healthcare announced its definitive agreement to acquire Lehan Drugs, Inc., a provider of home medical equipment based in Illinois, for $26 million. This strategic acquisition, expected to close in the third quarter of 2025, aims to diversify Viemed’s product offerings into maternal health and expand its market presence, leveraging Lehan’s established reputation and community engagement in the healthcare sector.
On April 14, 2025, Bruce Greenstein resigned from Viemed Healthcare‘s Board of Directors, where he served as Chairman of the Corporate Governance & Nominating Committee and a member of the Audit Committee. His resignation was not due to any disagreements with the company’s operations, policies, or practices, suggesting a smooth transition without immediate operational impacts.